Wave Life Sciences
Wave Life Sciences is a clinical-stage RNA medicines company using its proprietary PRISM platform to design stereopure oligonucleotides that target genetic diseases, metabolic disorders, and neurological conditions. Lead programs include WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD), WVE-003 for Huntington's disease, WVE-007 for obesity, and WVE-N531 for Duchenne muscular dystrophy, with a strategic collaboration with GSK to accelerate development of RNA-based therapeutics.
Company Info
Upcoming Milestones & Key Dates
WVE-006 (AATD) proof-of-mechanism data in patients
WVE-003 (Huntington's) updated safety and biomarker data
Clinical Development Pipeline
WVE-006
Target: A-to-I RNA editing oligonucleotide (AIMer)WVE-003
Target: Allele-selective antisense oligonucleotideWVE-N531
Target: Exon 53 skipping oligonucleotideWVE-007
Target: GalNAc-conjugated siRNA targeting INHBE in hepatocytesRecent News
No recent news updates available for this company.
Leadership Team
Careers & Job Openings